Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

Bezlotoxumab is human monoclonal antibody against Clostridium difficile toxin B. In two controlled trials, a single intravenous dose of bezlotoxumab, given in addition to antibiotic treatment, provided protection against recurrent infection for up to 12 weeks.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-01, Vol.376 (4), p.305-317
Hauptverfasser:	Wilcox, Mark H, Gerding, Dale N, Poxton, Ian R, Kelly, Ciaran, Nathan, Richard, Birch, Thomas, Cornely, Oliver A, Rahav, Galia, Bouza, Emilio, Lee, Christine, Jenkin, Grant, Jensen, Werner, Kim, You-Sun, Yoshida, Junichi, Gabryelski, Lori, Pedley, Alison, Eves, Karen, Tipping, Robert, Guris, Dalya, Kartsonis, Nicholas, Dorr, Mary-Beth
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use Antibiotics Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Neutralizing - adverse effects Antibodies, Neutralizing - therapeutic use Bacterial infections Body weight Clinical trials Clostridium difficile Clostridium Infections - prevention & control Data processing Diarrhea Double-Blind Method Drug therapy Drug Therapy, Combination Female Humans Infusions, Intravenous Intention to Treat Analysis Kaplan-Meier Estimate Male Middle Aged Monoclonal antibodies Motivation Nausea Preventive medicine Recurrent infection Secondary Prevention Subpopulations Toxins Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Bezlotoxumab is human monoclonal antibody against Clostridium difficile toxin B. In two controlled trials, a single intravenous dose of bezlotoxumab, given in addition to antibiotic treatment, provided protection against recurrent infection for up to 12 weeks.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1602615